Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AAD, Academy, accuracy, Acorda, Affentranger, Afsaneh, Alavi, albumin, alfa, ALX, anaphylatoxin, antigen, apremilast, ascending, asunercept, atezulizumab, Bain, baricitinib, beleggen, beta, BTK, Burton, buyer, carbon, CDO, cemiplimab, cephalosporin, chemical, chemotherapeutic, Chinese, cleantech, climate, clindamycin, concomitantly, cosibelimab, COSO, Cox, CPAP, cream, CSO, customarily, CXC, cybersecurity, cyclic, cytochrome, cytotoxic, dapsone, dataset, delivery, Dentistry, depemokimab, depiction, depressed, descedent, deteriorate, dialogue, disqualification, disruptor, Division, downturn, doxorubicin, drempel, dynamic, editing, effectual, ELR, en, EP, etrasimod, expressly, extracellular, extraordinary, extrapolated, fuel, furlough, fusion, gas, gave, gemcitabine, gene, genital, geopolitical, Gohibic, graph, greenhouse, grondslag, hamster, harmour, hazard, heart, heffingvrij, hemoglobinuria, HHS, hydrolase, ICT, imiquimod, immunoglobulin, imsidolimab, inkomen, insertion, Instruction, intralesionally, intramuscular, Intratumorally, invasively, ipilimumab, izokibeb, JAK, junior, Lastly, Leqembi, leukotriene, locoregional, logistic, logistical, LTI, MAP, Maraba, Mayo, meantime, media, Mei, MEK, melanoma, metabolism, metronidazole, micro, microtubule, military, monovalent, moratlity, mucin, myeloid, nangibotide, nanobody, nanrilkefusp, necessitating, neurological, neutropenia, nihil, NMPA, Noncurrent, nondepleting, nuclear, oil, oncolytic, orimsilast, orismilast, ORR, PANAMO, peildatum, Pemphigoid, people, peptide, peptidic, persistent, Peter, photoimmune, plasmin, Po, postpone, povorcitinib, printed, pustular, radical, radiological, regression, remibrutinib, rendement, rendementspercentage, reproduce, resistant, resorcinol, rifampicin, RIST, Road, robust, route, routine, ruxolitinib, sabizabulin, Samsung, sefe, sentiment, serum, session, shutdown, sixty, sonelokimab, spanning, sparen, spesolimab, Spinraza, stagnation, stipulated, stratification, subpopulation, subunit, sudden, summer, superagonist, superficial, synthetic, Tai, tapered, taxane, Tecfidera, tetracycline, thrombin, timeframe, timeline, tirbanibulin, tocilizumab, tolearated, tow, transgenic, trap, trivalent, tyrosine, unapproved, unexercised, unlocked, unqualified, unresectable, untreated, vector, vegetative, Veru, Vilwaysi, voordeel, wage, Ward, Western, wouldthen, zilicoplan, zunsemetinib
Removed:
abbvie, absolute, absorb, Affentrager, aggregation, al, Ammann, ANCOVA, Anstalt, arithmetic, Asia, asserted, attached, attest, avoided, Bausch, biopharma, Biovitrum, brand, characterize, chemocentryx, Chugai, CIMA, Cloud, conference, confirmation, congregating, convince, costimulation, degranulation, detrimental, DF, diagnosed, discretionary, DLQI, drop, easier, economy, elaborated, eleven, emergent, epyx, escalating, escalation, exacerbation, execution, expedited, explained, extendable, ffentlichen, fistula, Floor, Florida, France, functionality, Gall, Genentech, genitalia, globally, golden, graft, greatest, ground, grouped, handled, Hao, hindered, historic, host, Humira, Hurley, impacting, impairing, imputation, Incyte, insentia, internet, Investco, IXCHANGE, IXPLORE, Janssen, Japanese, Katrin, KfW, Kung, lab, LANexpert, Lina, LP, Ma, machinery, mandated, manuscript, medium, MINE, minimal, missing, MoA, modelling, moving, multicenter, nancial, nodule, nonbinding, numerical, NY, observational, offered, Ohio, OLE, oncology, Ortho, outbreak, parachute, path, percent, petition, Pharma, pharmacodynamic, poster, precautionary, preceded, prioritization, promoter, QUALITATIVE, QUANTITATIVE, quicker, ra, reform, remediation, Remicade, remote, remotely, rendementgrondslag, RESERVED, revealed, revision, rheumatoid, Ritximab, rose, Russia, Salix, SB, Schweiz, SILIQ, Sloan, solve, Squibb, stable, strongest, subset, surprisingly, suspending, Swedish, switching, tailored, TEAE, Technologie, terrorism, thousand, transitioning, translate, twelve, unblinding, unwilling, Uschmann, visit, Wang, war, weaken, weakened, weakening, weekly, Wilcoxon, window, Yautong, York, Zurich
Filing tables
Filing exhibits
- 20-F Annual report (foreign)
- 1.1 Articles of Association of Inflarx N.V., Dated August 25, 2021
- 2.4 Description of Rights of Each Applicable Class of Securities Registered Under Section 12 of the Securities Exchange Act of 1934.
- 4.4 Addendum No. 2, Dated As of November 9, 2022, Between Inflarx GMBH and Beijing Defengrei Biotechnology Co. LTD.
- 8.1 List of Subsidiaries
- 12.1 Certification
- 12.2 Certification
- 13.1 Certification
- 13.2 Certification
- 15.1 Consent of Ernst & Young GMBH Wirtschaftsprufungsgesellschaft
- Download Excel data file
- View Excel data file
IFRX similar filings
Filing view
External links
Exhibit 8.1
Subsidiaries of the Registrant
Entity name | Jurisdiction of organization | |
InflaRx GmbH | Germany | |
InflaRx Pharmaceuticals, Inc. | Delaware |